BMT CTN Protocol 0805 (SWOG 0805)

Phase II Study Of Combination Of Hyper-CVAD And Dasatinib With Or Without Allogeneic Stem Cell Transplant In Patients With Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)

Below are protocol-related documents, which may be periodically updated.

• Protocol, #15 dated April 23, 2014
• This study is posted on clinicaltrials.gov as NCT00792948
• Key Personnel

           SWOG Protocol Chair: Farhad Ravandi, MD fravandi@mdanderson.org

           BMT CTN Protocol Chair: David Porter, MD david.porter@uphs.upenn.edu

  This study was closed to new patient accrual on October 1, 2013.